85302-07-4

Basic information

• Product Name: 2-[(Dimethylamino)methylene]-1,3-cyclohexanedione
• Synonyms: 2-[(dimethylamino)methylene]-1;2-[(Dimethylamino)methylene]-1,3-cyclohexanedione;2-[(Dimethylamino)methylene]cyclohexane-1,3-dione;2-[(diMethylaMino)Methylidene]cyclohexane-1,3-dione
• CAS NO: 85302-07-4
• Molecular Formula: C₉H₁₃NO₂
• Molecular Weight: 167.21
• Mol File: 85302-07-4.mol
• Article Data: 54

Chemical Properties

• Melting Point: 116 °C(Solv: chloroform (67-66-3); ligroine (8032-32-4))
• Boiling Point: 274.5 °C at 760 mmHg
• Flash Point: 116 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 0.00539mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 3.11±0.20(Predicted)
• CAS DataBase Reference: 2-[(Dimethylamino)methylene]-1,3-cyclohexanedione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(Dimethylamino)methylene]-1,3-cyclohexanedione(85302-07-4)
• EPA Substance Registry System: 2-[(Dimethylamino)methylene]-1,3-cyclohexanedione(85302-07-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 85302-07-4(Hazardous Substances Data)

Usage

General Description

2-[(Dimethylamino)methylene]-1,3-cyclohexanedione, also known as dimedone, is a bicyclic diketone compound with a dimethylamino group attached to one of the carbon atoms. It is widely used in organic synthesis as a reactant in the formation of heterocyclic compounds, such as pyrazoles and pyrimidines, as well as in the synthesis of pharmaceuticals and agrochemicals. Dimedone is known for its versatile reactivity and ability to undergo various functional group transformations, making it a valuable building block in organic chemistry. It is also used in the detection of various radicals and reactive intermediates due to its ability to form stable adducts with them. Overall, dimedone is an important and versatile chemical compound with applications in both research and industrial settings.

InChI:InChI=1/C9H13NO2/c1-10(2)6-7-8(11)4-3-5-9(7)12/h6H,3-5H2,1-2H3

Upstream product

• 504-02-9 1,3-cylohexanedione 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 127-19-5 N,N-dimethyl acetamide 
• 1193-55-1 2-methylcyclohexane-1,3-dione 
• 18503-89-4 N,N-dimethylformamide diisopropyl acetal 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 145430-29-1 5-Oxo-2-phenyl-5,6,7,8-tetrahydro-2H-<1>benzothiopyran-3-carbaldehyde 
• 92856-34-3 3-benzoylamino-5-oxo-5,6,7,8-tetrahydrocoumarin 
• 87379-57-5 3-Hydroxy-2-iminomethyl-cyclohex-2-enone 
• 21599-36-0 2-amino-7,8-dihydroquinazolin-5(6H)-one 
• 113502-42-4 chlorhydrate d'(amidino-2 hydrazino)methylene-2 cyclohexanedione-1,3 
• 27282-89-9 amino-2 methylthio-4 triazine-1,3,5 
• 21599-35-9 2-(methylthio)-7,8-dihydroquinazolin-5(6H)-one 
• 21599-29-1 7,8-dihydro-(2-methyl)quinazolin-5(6H)-one 
• 115310-16-2 1,5,6,7-tetrahydro-1-(phenylmethyl)indazol-4-one 
• 87287-41-0 6,7-Dihydro-5H-benzo[d]isoxazol-4-one 
• 41732-10-9 2-Hydroxy-6-oxo-cyclohex-1-enecarbonitrile 
• 21599-31-5 2-phenyl-7,8-dihydroquinazolin-5(6H)-one 
• 14823-31-5 4-Oxo-1-phenyl-4,5,6,7-tetrahydrobenopyrazole 
• 85302-16-5 1-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazole 

Relevant articles and documents

NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF HAEMATOLOGICAL PATHOLOGIES

The present invention relates to compounds having a tetracyclic system and the use thereof as new therapeutic agents in the treatment of acute myeloid leukemia (AML), preferably in FLT3/ITD hemizygote patients resistant to conventional therapies. The invention also relates to 5,7-dihydro-4H-[1,3]thiazolo[4,5-e]isoindol-2-amine compounds useful as intermediates for the synthesis of tetracyclic imidazo[2',1':2,3][1,3]thiazolo[4,5-e]isoindole compounds.

Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold

Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease conditions. The ubiquitous localization of these enzymes and the high homology shared by the different isoforms represent substantial impediments for the

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.